keyword
https://read.qxmd.com/read/38534423/research-progress-of-nanomaterials-acting-on-nk-cells-in-tumor-immunotherapy-and-imaging
#1
REVIEW
Yachan Feng, Haojie Zhang, Jiangtao Shao, Chao Du, Xiaolei Zhou, Xueling Guo, Yingze Wang
The prognosis for cancer patients has declined dramatically in recent years due to the challenges in treating malignant tumors. Tumor immunotherapy, which includes immune target inhibition and chimeric antigen receptor cell treatment, is currently evolving quickly. Among them, natural killer (NK) cells are gradually becoming another preferred cell immunotherapy after T cell immunotherapy due to their unique killing effects in innate and adaptive immunity. NK cell therapy has shown encouraging outcomes in clinical studies; however, there are still some problems, including limited efficacy in solid tumors, inadequate NK cell penetration, and expensive treatment expenses...
February 27, 2024: Biology
https://read.qxmd.com/read/38534399/modulating-cholesterol-metabolism-via-acat1-knockdown-enhances-anti-b-cell-lymphoma-activities-of-cd19-specific-chimeric-antigen-receptor-t-cells-by-improving-the-cell-activation-and-proliferation
#2
JOURNAL ARTICLE
Qiong Su, Jie Yao, Muhammad Asad Farooq, Iqra Ajmal, Yixin Duan, Cong He, Xuefei Hu, Wenzheng Jiang
CD19-specific CAR-T immunotherapy has been extensively studied for the treatment of B-cell lymphoma. Recently, cholesterol metabolism has emerged as a modulator of T lymphocyte function and can be exploited in immunotherapy to increase the efficacy of CAR-based systems. Acetyl-CoA acetyltransferase 1 (ACAT1) is the major cholesterol esterification enzyme. ACAT1 inhibitors previously shown to modulate cardiovascular diseases are now being implicated in immunotherapy. In the present study, we achieved knockdown of ACAT1 in T cells via RNA interference technology by inserting ACAT1-shRNA into anti-CD19-CAR-T cells...
March 21, 2024: Cells
https://read.qxmd.com/read/38534054/successful-treatment-of-refractory-orbital-plasmacytoma-with-chimeric-antigen-receptor-t-cell-therapy-a-case-report-and-review-of-the-literature
#3
JOURNAL ARTICLE
Rebecca Z Lin, Tracy Lu, Natalie Homer, Clara J Men
Orbital plasmacytoma is a rare plasma cell tumor that may arise as an aggressive form of extramedullary multiple myeloma. Treatment modalities include surgical excision, radiation, and chemotherapy. Chimeric antigen receptor T cell therapy is currently reserved for refractory disease. The authors present a case of a 69-year-old woman with an extensive orbital plasmacytoma refractory to multimodal therapy who was treated with idecabtagene vicleucel chimeric antigen receptor T cell therapy. Four days after infusion, the patient exhibited grade 1 cytokine release syndrome, which resolved with tocilizumab...
March 21, 2024: Ophthalmic Plastic and Reconstructive Surgery
https://read.qxmd.com/read/38533510/redefining-the-battle-against-colorectal-cancer-a-comprehensive-review-of-emerging-immunotherapies-and-their-clinical-efficacy
#4
REVIEW
Salima Shebbo, Najat Binothman, Manar Darwaish, Hanan A Niaz, Rwaa H Abdulal, Jamilah Borjac, Anwar M Hashem, Ahmad Bakur Mahmoud
Colorectal cancer (CRC) is the third most common cancer globally and presents a significant challenge owing to its high mortality rate and the limitations of traditional treatment options such as surgery, radiotherapy, and chemotherapy. While these treatments are foundational, they are often poorly effective owing to tumor resistance. Immunotherapy is a groundbreaking alternative that has recently emerged and offers new hope for success by exploiting the body's own immune system. This article aims to provide an extensive review of clinical trials evaluating the efficacy of various immunotherapies, including CRC vaccines, chimeric antigen receptor T-cell therapies, and immune checkpoint inhibitors...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38532515/inflammation-and-acute-cardiotoxicity-in-adult-hematological-patients-treated-with-car-t-cells-results-from-a-pilot-proof-of-concept-study
#5
JOURNAL ARTICLE
Massimiliano Camilli, Marcello Viscovo, Tamara Felici, Luca Maggio, Federico Ballacci, Giacomo Carella, Alice Bonanni, Priscilla Lamendola, Lorenzo Tinti, Antonio Di Renzo, Giulia Coarelli, Eugenio Galli, Giovanna Liuzzo, Francesco Burzotta, Rocco Antonio Montone, Federica Sorà, Simona Sica, Stefan Hohaus, Gaetano Antonio Lanza, Filippo Crea, Antonella Lombardo, Giorgio Minotti
AIMS: Chimeric Antigen Receptor-T (CAR-T) cell infusion is a rapidly evolving antitumor therapy; however, cardiovascular (CV) complications, likely associated with cytokine release syndrome (CRS) and systemic inflammation, have been reported to occur. The CARdio-Tox study aimed at elucidating incidence and determinants of cardiotoxicity related to CAR-T cell therapy. METHODS: Patients with blood malignancies candidate to CAR-T cells were prospectively evaluated by echocardiography at baseline and 7 and 30 days after infusion...
March 27, 2024: Cardio-Oncology
https://read.qxmd.com/read/38530240/induction-of-immortal-like-and-functional-car-t-cells-by-defined-factors
#6
JOURNAL ARTICLE
Lixia Wang, Gang Jin, Qiuping Zhou, Yanyan Liu, Xiaocui Zhao, Zhuoyang Li, Na Yin, Min Peng
Long-term antitumor efficacy of chimeric antigen receptor (CAR) T cells depends on their functional persistence in vivo. T cells with stem-like properties show better persistence, but factors conferring bona fide stemness to T cells remain to be determined. Here, we demonstrate the induction of CAR T cells into an immortal-like and functional state, termed TIF. The induction of CARTIF cells depends on the repression of two factors, BCOR and ZC3H12A, and requires antigen or CAR tonic signaling. Reprogrammed CARTIF cells possess almost infinite stemness, similar to induced pluripotent stem cells while retaining the functionality of mature T cells, resulting in superior antitumor effects...
May 6, 2024: Journal of Experimental Medicine
https://read.qxmd.com/read/38530182/erratum-for-direct-and-indirect-chimeric-antigen-receptor-t-cell-imaging-with-pet-mri-in-a-tumor-xenograft-model
#7
Seog-Young Kim, Hyunsu Soh, Jin Hwa Jung, Eun Hye Cho, Hyori Kim, Ji-Min Ju, Joong Hyuk Sheen, Sang Ju Lee, Seung Jun Oh, Sang-Jin Lee, Junho Chung, Jin-Sook Ryu
No abstract text is available yet for this article.
March 2024: Radiology
https://read.qxmd.com/read/38528698/ct-demonstration-of-local-cytokine-release-syndrome-involving-the-head-and-neck-following-chimeric-antigen-receptor-t-cell-infusion-therapy
#8
EDITORIAL
Ji Su Ko, Jeong Hyun Lee, Dok Hyun Yoon, Chong Hyun Suh, Sae Rom Chung, Young Jun Choi, Jung Hwan Baek
No abstract text is available yet for this article.
April 2024: Korean Journal of Radiology: Official Journal of the Korean Radiological Society
https://read.qxmd.com/read/38527842/-safety-and-efficacy-of-donor-derived-chimeric-antigen-receptor-t-cell-therapy-in-patients-with-relapsed-b-cell-acute-lymphoblastic-leukemia-after-allogeneic-hematopoietic-stem-cell-transplantation
#9
JOURNAL ARTICLE
Y Q Zhuo, S F Tu, X Zhou, J L Yang, L J Zhou, R Huang, Y X Huang, M F Li, B Jin, B Wang, S Q Li, Z T Yuan, L H Zhang, L Liu, S B Wang, Y H Li
Objective: To investigated the safety and efficacy of donor-derived CD19+ or sequential CD19+ CD22+ chimeric antigen receptor T-cell (CAR-T) therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: The data of 22 patients with B-ALL who relapsed after allo-HSCT and who underwent donor-derived CAR-T therapy at the Zhujiang Hospital of Southern Medical University and the 920th Hospital of Joint Logistics Support Force of the People's Liberation Army of China from September 2015 to December 2022 were retrospectively analyzed...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527836/-efficacy-and-safety-of-chimeric-antigen-receptor-t-cell-therapy-followed-by-allogeneic-hematopoietic-stem-cell-transplantation-in-21-patients-with-ph-like-acute-lymphoblastic-leukemia
#10
JOURNAL ARTICLE
H P Dai, H J Shen, Z Li, W Cui, Q Y Cui, M Y Li, S F Chen, M Q Zhu, D P Wu, X W Tang
Objective: To evaluate the efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with Ph-like acute lymphoblastic leukemia (Ph-ALL) . Methods: Patients with Ph-ALL who underwent CAR-T therapy followed by allo-HSCT from March 2018 to August 2023 at the First Affiliated Hospital of Soochow University were included, and their clinical data were retrospectively analyzed. Results: Of the 21 patients, 14 were male and 7 were female...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527265/tumor-infiltrating-lymphocyte-and-other-cell-therapies-for-metastatic-melanoma
#11
JOURNAL ARTICLE
Christy Los, Sebastian Klobuch, John B A G Haanen
Major progress in prolonging survival of patients with advanced melanoma has been made in the past decade because of the development and approval of immune checkpoint inhibitor and targeted therapies. However, for nonresponding or relapsing patients, their prognosis is still dismal. Based on clinical trial data, treatment with adoptive cell therapies holds great promise. In patients with metastatic melanoma progressing on or nonresponsive to single-agent anti-programmed cell death 1, infusion of tumor-infiltrating lymphocytes can produce responses in up to half of patients, with durable complete responses in up to 20%...
March 2024: Cancer Journal
https://read.qxmd.com/read/38525009/emerging-strategies-to-overcome-current-car-t-therapy-dilemmas-exosomes-derived-from-car-t-cells
#12
REVIEW
Dong Hu, Ruyue Yang, Guidan Wang, Hao Li, Xulong Fan, Gaofeng Liang
Adoptive T cells immunotherapy, specifically chimeric antigen receptor T cells (CAR-T), has shown promising therapeutic efficacy in the treatment of hematologic malignancies. As extensive research on CAR-T therapies has been conducted, various challenges have emerged that significantly hampered their clinical application, including tumor recurrence, CAR-T cell exhaustion, and cytokine release syndrome (CRS). To overcome the hurdles of CAR-T therapy in clinical treatment, cell-free emerging therapies based on exosomes derived from CAR-T cells have been developed as an effective and promising alternative approach...
2024: International Journal of Nanomedicine
https://read.qxmd.com/read/38524535/exploring-cellular-immunotherapy-platforms-in-multiple-myeloma
#13
REVIEW
Manh-Cuong Vo, Sung-Hoon Jung, Van-Tan Nguyen, Van-Dinh-Huan Tran, Nodirjon Ruzimurodov, Sang Ki Kim, Xuan-Hung Nguyen, Mihee Kim, Ga-Young Song, Seo-Yeon Ahn, Jae-Sook Ahn, Deok-Hwan Yang, Hyeoung-Joon Kim, Je-Jung Lee
Despite major advances in therapeutic platforms, most patients with multiple myeloma (MM) eventually relapse and succumb to the disease. Among the novel therapeutic options developed over the past decade, genetically engineered T cells have a great deal of potential. Cellular immunotherapies, including chimeric antigen receptor (CAR) T cells, are rapidly becoming an effective therapeutic modality for MM. Marrow-infiltrating lymphocytes (MILs) derived from the bone marrow of patients with MM are a novel source of T cells for adoptive T-cell therapy, which robustly and specifically target myeloma cells...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38524122/corrigendum-regulatory-t-cells-targeting-a-pathogenic-mhc-class-ii-insulin-peptide-epitope-postpone-spontaneous-autoimmune-diabetes
#14
Nyerhovwo Obarorakpor, Deep Patel, Reni Boyarov, Nansalmaa Amarsaikhan, Joseph Ray Cepeda, Doreen Eastes, Sylvia Robertson, Travis Johnson, Kai Yang, Qizhi Tang, Li Zhang
[This corrects the article DOI: 10.3389/fimmu.2023.1207108.].
2024: Frontiers in Immunology
https://read.qxmd.com/read/38517338/chimeric-antigen-receptors-cars-in-the-fast-lane-for-rheumatology
#15
JOURNAL ARTICLE
Nathan M Johnson, Fotios Koumpouras
PURPOSE OF REVIEW: Recent advances in hematology-oncology have pioneered cell-mediated elimination of pathologic B-cell populations employing chimeric antigen receptor (CAR) T cells. In this review, we discuss recent adoption of CAR-T treatment for severe refractory autoimmune disease. We highlight unique aspects of the autoimmune model and review current clinical data regarding treatment of rheumatologic disease. RECENT FINDINGS: To date, several CAR-Ts are FDA approved for Multiple Myeloma and B-cell malignancies and have demonstrated extraordinary clinical responses in refractory disease...
May 1, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/38517027/high-cd62l-expression-predicts-the-generation-of-chimeric-antigen-receptor-t-cells-with-potent-effector-functions
#16
JOURNAL ARTICLE
Hitomi Kasuya, Haosong Zhang, Yusuke Ito, Toshiaki Yoshikawa, Takahiro Nakashima, Yang Li, Tetsuya Matsukawa, Satoshi Inoue, Yuki Kagoya
Efficient generation of chimeric antigen receptor (CAR) T cells is highly influenced by the quality of apheresed T cells. Healthy donor-derived T cells usually proliferate better than patients-derived T cells and are precious resources to generate off-the-shelf CAR-T cells. However, relatively little is known about the determinants that affect the efficient generation of CAR-T cells from healthy donor-derived peripheral blood mononuclear cells (PBMC) compared with those from the patients' own PBMC. We here examined the efficiency of CAR-T cell generation from multiple healthy donor samples and analyzed its association with the phenotypic features of the starting peripheral blood T cells...
March 22, 2024: International Immunology
https://read.qxmd.com/read/38516299/car-designs-for-solid-tumors-overcoming-hurdles-and-paving-the-way-for-effective-immunotherapy
#17
JOURNAL ARTICLE
Yuanbin Cui, Mintao Luo, Chuanyuan Gu, Yuxian He, Yao Yao, Peng Li
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized immunotherapy by modifying patients' immune cells genetically. By expressing CARs, these modified cells can specifically identify and eliminate tumor cells. The success of CAR-T therapy in hematological malignancies, such as leukemia and lymphoma, has been remarkable. Numerous studies have reported improved patient outcomes and increased survival rates. However, the application of CAR-T therapy in treating solid tumors faces significant challenges...
October 31, 2023: Biophysics Reports
https://read.qxmd.com/read/38515237/nucleic-acid-based-vaccine-for-ovarian-cancer-cells-bench-to-bedside
#18
REVIEW
Sulieman Ibraheem Shelash Al-Hawary, Saade Abdalkareem Jasim, Ahmed Hjazi, Enwa Felix Oghenemaro, Irwanjot Kaur, Abhinav Kumar, Ahmed Muzahem Al-Ani, Enas R Alwaily, Ahmed Huseen Redhee, Yasser Fakri Mustafa
Ovarian cancer continues to be a difficult medical issue that affects millions of individuals worldwide. Important platforms for cancer immunotherapy include checkpoint inhibitors, chimeric antigen receptor T cells, bispecific antibodies, cancer vaccines, and other cell-based treatments. To avoid numerous infectious illnesses, conventional vaccinations based on synthetic peptides, recombinant subunit vaccines, and live attenuated and inactivated pathogens are frequently utilized. Vaccine manufacturing processes, however, are not entirely safe and carry a significant danger of contaminating living microorganisms...
March 2024: Cell Biochemistry and Function
https://read.qxmd.com/read/38514793/early-induction-of-cytokine-release-syndrome-by-rapidly-generated-car-t-cells-in-preclinical-models
#19
JOURNAL ARTICLE
Arezoo Jamali, Naphang Ho, Angela Braun, Elham Adabi, Frederic B Thalheimer, Christian J Buchholz
Cytokine release syndrome (CRS) is a significant side-effect of conventional chimeric antigen receptor (CAR) T-cell therapy. To facilitate patient accessibility, short-term (st) CAR T cells, which are administered to patients only 24 h after vector exposure, are in focus of current investigations. Their impact on the incidence and severity of CRS has been poorly explored. Here, we evaluated CD19-specific stCAR T cells in preclinical models. In co-culture with tumor cells and monocytes, stCAR T cells exhibited anti-tumoral activity and potent release of CRS-related cytokines (IL-6, IFN-γ, TNF-α, GM-CSF, IL-2, IL-10)...
March 21, 2024: EMBO Molecular Medicine
https://read.qxmd.com/read/38514103/-hematologic-diseases-and-neurological-complications
#20
JOURNAL ARTICLE
Naoki Omori, Atsushi Nagai
Many hematologic diseases can be complicated by neurological symptoms during the disease course. Hematologic diseases can contribute to strokes and neuropathies; thus, neurologists should be aware of them. Recent reports have increased of neurological side effects associated with new anticancer therapies such as immune checkpoint inhibitors and chimeric antigen receptor-T cell therapy. The relationship between hematologic diseases and neurological complications is expected to become more prevalent.
March 2024: Brain and Nerve, Shinkei Kenkyū No Shinpo
keyword
keyword
59418
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.